Author

V. DeMambro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. A. Gumerova· 1 shared A. Cao· 1 shared A. D'Amico· 1 shared A. Macdonald· 1 shared A. Padilla· 1 shared A. Teunissen· 1 shared C. Falank· 1 shared C. G. Gartner· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. A. Gumerova

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Fatty Acid Binding Protein Family Represents a Novel Target in Multiple Myeloma

M. Farrell, H. Fairfield, M. Karam, A. D'Amico, C. S. Murphy, C. Falank, R. S. Pistofidi, A. Cao, C. R. Marinac, J. A. Dragon, L. McGuinness, C. G. Gartner, R. D. Iorio, E. Jachimowicz, V. DeMambro, , M. R. Reagan

This paper identifies the fatty acid binding protein (FABP) family as a novel therapeutic target in multiple myeloma, showing that FABP inhibition reduces tumor growth and alters key cellular processes.

eLife · Mar 7, 2023Peer-reviewedCancer Biology

A Single Multipurpose FSH-Blocking Therapeutic for Osteoporosis and Obesity

S. Gera, T.-C. Kuo, F. Korkmaz, D. Sant, V. DeMambro, A. A. Gumerova, K. Sudha, A. Padilla, G. Prevot, J. Munitz, A. Teunissen, M. M. T. van Leent, T. G. J. M. Post, J. C. Fernandes, J. Netto, , M. Zaidi

This paper develops and tests a first-in-class FSH-blocking antibody, MS-Hu6, showing efficacy in preventing obesity and osteoporosis in mice and safety in monkeys.

bioRxiv · Feb 28, 2022 · PreprintPharmacology & Toxicology